- Home
- SPRY
as 05-30-2025 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $28.75 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.55 - $18.51 | Next Earning Date: | 05-14-2025 |
| Revenue: | $97,122,000 | Revenue Growth: | 971120.00% |
| Revenue Growth (this year): | 1.49% | Revenue Growth (next year): | 141.68% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scott Kathleen D. | SPRY | Chief Financial Officer | May 20 '25 | Sell | $14.10 | 50,000 | $705,165.00 | 7,424 | |
| Fitzpatrick Alexander A | SPRY | Chief Legal Officer | May 20 '25 | Sell | $14.10 | 102,969 | $1,451,512.81 | 89,613 | |
| Shawver Laura | SPRY | Director | Apr 7 '25 | Sell | $12.30 | 50,002 | $615,074.60 | 210,346 | |
| Karas Eric | SPRY | Chief Commercial Officer | Mar 20 '25 | Sell | $14.00 | 10,000 | $140,000.00 | 7,696 | |
| Shawver Laura | SPRY | Director | Mar 5 '25 | Sell | $11.11 | 50,000 | $560,445.76 | 210,346 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
Simply Wall St.
10 days ago
Exploring US High Growth Tech Stocks In May 2025
Simply Wall St.
17 days ago
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today
GuruFocus.com
17 days ago
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ...
Thomson Reuters StreetEvents
17 days ago
Q1 2025 ARS Pharmaceuticals Inc Earnings Call
Zacks
18 days ago
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
MT Newswires
18 days ago
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates
GlobeNewswire
18 days ago
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.